Publications by authors named "Pavlina Dzekova"
Background: A consensus about the optimal timing of dialysis initiation is still controversial. Thus, the goal of this analysis was to compare outcomes in patients with early and late referral with early and late initiation of hemodialysis (HD).
Methods: We studied 190 patients (mean age 52.
Advanced glycation end-products (AGEs) are uremic toxins that accumulate progressively in hemodialysis (HD) patients. The aim of this study was to assess the 1-year increase in skin autofluorescence (ΔAF), a measure of AGEs accumulation and plasma markers, as predictors of mortality in HD patients. One hundred sixty-nine HD patients were enrolled in this study.
View Article and Find Full Text PDFArticle Synopsis
- Hepatitis C is linked to increased oxidative stress and the buildup of advanced glycation end products (AGEs), which heightens the risk of cardiovascular disease (CVD) in patients undergoing haemodialysis.
- In a study comparing 92 haemodialysis patients with 93 healthy controls, significant differences in AGE accumulation were found, with haemodialysis patients exhibiting higher levels of skin autofluorescence (AF).
- The research concluded that while AGE accumulation was greater in haemodialysis patients compared to healthy individuals, hepatitis C infection did not influence AGE levels, suggesting factors like age, diabetes mellitus (DM), and CVD are more critical in this population.
Purpose: The aim of this study was to evaluate the persistence of sustained viral response after treatment of hepatitis C with pegylated interferon alpha-2a in hemodialysis patients.
Methods: 14 hemodialysis patients with chronic hepatitis C were treated with pegylated interferon alpha-2a for a period of 48 weeks. Achieved sustained viral response rate was 35.
Background: The high prevalence of hepatitis C virus (HCV) infection in hemodialysis patients is of great concern because they have a higher rate of mortality than HCV-negative hemodialysis patients. The aim of the study was to evaluate the efficacy and safety of pegylated interferon alpha-2a monotherapy in hemodialysis patients with chronic HCV infection.
Methods: Fourteen dialysis patients with chronic HCV infection were scheduled to receive 135 mug pegylated interferon alpha-2a subcutaneously, once a week, after dialysis session for a period of 48 weeks.